AI Article Synopsis
- Hepatocellular carcinoma (HCC) is a major global health issue, especially prevalent in nonindustrialized nations and increasingly common in industrialized regions.
- Sorafenib was introduced in 2007 as the first main treatment for unresectable HCC, but recent developments, particularly the 2020 trials, have shifted the focus to the combination of atezolizumab and bevacizumab, which outperformed sorafenib.
- This monograph reviews the safety and efficacy of atezolizumab in HCC treatment, both as a standalone option and in conjunction with other therapies.
Article Abstract
Hepatocellular carcinoma (HCC) is a worldwide problem, with a high prevalence in nonindustrialized countries and a rising incidence in industrialized countries. Its close association with chronic liver diseases and liver cirrhosis represents a significant challenge in its treatment. Sorafenib, the first front-line systemic treatment for unresectable HCC cases, was approved only in 2007. The role of sorafenib remained largely unchallenged until very recently, with the sole exception of a trial demonstrating the noninferiority of lenvatinib, another tyrosine kinase inhibitor. The therapeutic scenario changed dramatically in 2020, when the combination of atezolizumab and bevacizumab proved to be significantly superior to sorafenib and, thus, establishing a new standard of care. In this monograph we provide an update about the safety and efficacy of atezolizumab reported in the clinical trials of HCC, as monotherapy or in combination with other agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1358/dot.2021.57.6.3264116 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!